MX2024007345A - Pautas posologicas para el estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas. - Google Patents
Pautas posologicas para el estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas.Info
- Publication number
- MX2024007345A MX2024007345A MX2024007345A MX2024007345A MX2024007345A MX 2024007345 A MX2024007345 A MX 2024007345A MX 2024007345 A MX2024007345 A MX 2024007345A MX 2024007345 A MX2024007345 A MX 2024007345A MX 2024007345 A MX2024007345 A MX 2024007345A
- Authority
- MX
- Mexico
- Prior art keywords
- rur20kd
- related compositions
- compositions
- selective treg
- dosage guidelines
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940126892 rezpegaldesleukin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289371P | 2021-12-14 | 2021-12-14 | |
| US202263323126P | 2022-03-24 | 2022-03-24 | |
| US202263325923P | 2022-03-31 | 2022-03-31 | |
| US202263343505P | 2022-05-18 | 2022-05-18 | |
| US202263374632P | 2022-09-06 | 2022-09-06 | |
| PCT/US2022/081541 WO2023114833A1 (en) | 2021-12-14 | 2022-12-14 | Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007345A true MX2024007345A (es) | 2024-09-30 |
Family
ID=85157281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007345A MX2024007345A (es) | 2021-12-14 | 2022-12-14 | Pautas posologicas para el estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250049934A1 (https=) |
| EP (1) | EP4447995A1 (https=) |
| JP (1) | JP2024546803A (https=) |
| KR (1) | KR20240123817A (https=) |
| AU (1) | AU2022414070A1 (https=) |
| CA (1) | CA3239501A1 (https=) |
| IL (1) | IL313567A (https=) |
| MX (1) | MX2024007345A (https=) |
| WO (1) | WO2023114833A1 (https=) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401756A (en) | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| US5153310A (en) | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
| US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| FR2826365B1 (fr) | 2001-06-20 | 2003-09-26 | Oreal | Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile |
| EP2644206B1 (en) | 2003-05-23 | 2019-04-03 | Nektar Therapeutics | PEG derivatives containing two PEG chains |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| US7567215B1 (en) | 2007-10-23 | 2009-07-28 | The United States Of America As Represented By The Secretary Of The Navy | Portable and inflatable antenna device |
| WO2012065086A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
| BR112020021564A2 (pt) | 2018-05-21 | 2021-03-02 | Nektar Therapeutics | estimulador de treg seletivo rur20kd-il-2 e composições relacionadas |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
| CA3119439A1 (en) | 2018-11-09 | 2020-05-14 | Regenex LLC | Treatment method for graft-versus-host disease |
| CA3122843A1 (en) | 2018-12-12 | 2020-06-18 | The Brigham And Women's Hospital, Inc. | Compositions and methods for immunosuppression |
| EP4150060A4 (en) | 2020-05-13 | 2024-06-19 | Rapa Therapeutics, LLC | TREATMENT OR PREVENTION OF PRO-INFLAMMATORY DISEASES OR CONDITIONS USING INDUCED REGULATORY T CELLS (IT) |
-
2022
- 2022-12-14 EP EP22851299.2A patent/EP4447995A1/en active Pending
- 2022-12-14 MX MX2024007345A patent/MX2024007345A/es unknown
- 2022-12-14 WO PCT/US2022/081541 patent/WO2023114833A1/en not_active Ceased
- 2022-12-14 US US18/718,703 patent/US20250049934A1/en active Pending
- 2022-12-14 AU AU2022414070A patent/AU2022414070A1/en active Pending
- 2022-12-14 CA CA3239501A patent/CA3239501A1/en active Pending
- 2022-12-14 JP JP2024534714A patent/JP2024546803A/ja active Pending
- 2022-12-14 KR KR1020247022370A patent/KR20240123817A/ko active Pending
- 2022-12-14 IL IL313567A patent/IL313567A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022414070A1 (en) | 2024-05-16 |
| IL313567A (en) | 2024-08-01 |
| KR20240123817A (ko) | 2024-08-14 |
| WO2023114833A9 (en) | 2023-09-21 |
| US20250049934A1 (en) | 2025-02-13 |
| CA3239501A1 (en) | 2023-06-22 |
| JP2024546803A (ja) | 2024-12-26 |
| EP4447995A1 (en) | 2024-10-23 |
| WO2023114833A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| CY1125786T1 (el) | Οι διαρυλικοι μακροκυκλοι ως ρυθμιστες πρωτεϊνικων κινασων | |
| CY1126255T1 (el) | Χρησεις ανταγωνιστων il-13 για την αγωγη της ατοπικης δερματιτιδας | |
| MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
| BR112017000470A2 (pt) | composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| PH12020500576A1 (en) | Method of treating cancers with antagonistic anti-pd-1 antibodies | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| MX2017015938A (es) | Inhibidores de ezh2 para el tratar linfomas. | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| BR112017005209A2 (pt) | compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso | |
| BR112015023203A2 (pt) | métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| MX2024013040A (es) | Pirfenidona enriquecida con deuterio y metodos para su uso | |
| BR112018074152A8 (pt) | Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico | |
| MX2021007453A (es) | Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo. | |
| ZA202400851B (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
| MX2024009188A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. | |
| EP4477265A3 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| MX2023006368A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. | |
| BR112016016901A2 (pt) | agentes para o uso no tratamento de inflamação retinal | |
| MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. |